Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Evotec SE buy ShortPayable90

Start price
€5.95
16.08.24 / 50%
Target price
-
16.09.24
Performance (%)
7.40%
Price
€6.39
28.08.24
Summary
This prediction is currently active. The BUY prediction by ShortPayable90 shows slight gains of 7.40%. This prediction currently runs until 16.09.24. The prediction end date can be changed by ShortPayable90 at any time. ShortPayable90 has 50% into this prediction

Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.

Performance without dividends (%)
Name 1w
Evotec SE 15.447%
iShares Core DAX® 1.743%
iShares Nasdaq 100 -2.088%
iShares Nikkei 225® 1.306%
iShares S&P 500 -0.093%

Comments by ShortPayable90 for this prediction